Andra AP fonden Acquires Shares of 16,600 Revolution Medicines, Inc. $RVMD

Andra AP fonden acquired a new stake in shares of Revolution Medicines, Inc. (NASDAQ:RVMD) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 16,600 shares of the company’s stock, valued at approximately $1,614,000.

Several other large investors have also recently made changes to their positions in the company. Indiana Trust & Investment Management Co purchased a new position in shares of Revolution Medicines in the fourth quarter valued at $32,000. Global Retirement Partners LLC raised its stake in Revolution Medicines by 1,002.8% during the fourth quarter. Global Retirement Partners LLC now owns 397 shares of the company’s stock valued at $32,000 after purchasing an additional 361 shares in the last quarter. Torren Management LLC purchased a new stake in Revolution Medicines during the fourth quarter valued at $33,000. Arax Advisory Partners bought a new position in Revolution Medicines during the fourth quarter valued at $38,000. Finally, Darwin Wealth Management LLC purchased a new position in shares of Revolution Medicines in the 4th quarter worth $40,000. 94.34% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on RVMD. Wedbush boosted their target price on shares of Revolution Medicines from $181.00 to $192.10 and gave the stock an “outperform” rating in a report on Thursday. Piper Sandler increased their price target on shares of Revolution Medicines to $172.00 and gave the company an “overweight” rating in a report on Thursday, May 7th. Oppenheimer lifted their price target on Revolution Medicines from $165.00 to $195.00 and gave the stock an “outperform” rating in a research report on Monday, June 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Revolution Medicines in a research report on Friday, July 17th. Finally, Mizuho upped their price objective on Revolution Medicines from $185.00 to $215.00 and gave the company an “outperform” rating in a research report on Monday, July 6th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Revolution Medicines has an average rating of “Moderate Buy” and a consensus target price of $144.67.

Insider Transactions at Revolution Medicines

In other news, CFO Jack Anders sold 20,000 shares of the stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $168.33, for a total value of $3,366,600.00. Following the sale, the chief financial officer directly owned 123,269 shares in the company, valued at approximately $20,749,870.77. This represents a 13.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Margaret A. Horn sold 29,600 shares of the firm’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $160.12, for a total value of $4,739,552.00. Following the sale, the chief operating officer directly owned 154,647 shares of the company’s stock, valued at $24,762,077.64. This represents a 16.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 132,497 shares of company stock valued at $21,470,486. Company insiders own 7.60% of the company’s stock.

Revolution Medicines Stock Performance

Shares of NASDAQ:RVMD opened at $188.75 on Friday. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.19. Revolution Medicines, Inc. has a 12 month low of $34.00 and a 12 month high of $193.82. The company has a market capitalization of $40.13 billion, a price-to-earnings ratio of -26.70 and a beta of 1.37. The firm’s 50-day moving average is $168.00 and its 200 day moving average is $131.32.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($2.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.83) by ($0.46). During the same period last year, the company earned ($1.13) EPS. Research analysts predict that Revolution Medicines, Inc. will post -7.9 EPS for the current year.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.